RxDoctor Payments Data

Brain Dolsey, MD

Interventional Cardiology · Toledo, OHNPI 1508984956

Payments from drug & device makers

$3,879in general payments, 2019–2025

Across 96 payments — averaging $40.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Shockwave Medical, Inc$636
  • Inari Medical, Inc.$244
  • AstraZeneca$218
  • Abiomed$155
  • Cardiovascular Systems Inc.$147
  • plus $963 from 20 others

What the payments were for

  • Travel & lodging$1,20131%
  • Food & beverage$2,67869%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,879 in reported general payments places this provider in the 40th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$162,119
Medicare patients
1,320
Services billed
2,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$101,239
XareltoRivaroxaban27$23,179
Repatha SureclickEvolocumab12$8,665
Metoprolol Succinate102$1,296
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$1,020
Warfarin Sodium56$1,008
Ezetimibe18$927
Atorvastatin Calcium100$879
Losartan Potassium46$516
Potassium Chloride14$496
Isosorbide Mononitrate ErIsosorbide Mononitrate40$492
Carvedilol69$441
Rosuvastatin Calcium27$383
Amlodipine Besylate43$290
ClopidogrelClopidogrel Bisulfate44$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$101,239101 claims
Johnson & JohnsonXarelto$66$23,17927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →